Venetoclax monotherapy as front-line therapy for blastic plasmacytoid dendritic cell neoplasm

Venetoclax monotherapy as front-line therapy for blastic plasmacytoid dendritic cell neoplasm

Venetoclax is an approved treatment for relapsed/refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). We report a unique case of venetoclax monotherapy used for front-line induction and as a bridge to allogeneic hematopoietic stem cell transplantation (HCT). Venetoclax therapy resulted i...

Full description

Bibliographic Details
Main Authors: Ankit Mitesh Shah, Denise Pereira, Julio Poveda, Trent Peng Wang
Format: Article
Language:English
Published: Elsevier 2023-01-01
Series:Leukemia Research Reports
Subjects:
Blastic plasmacytoid dendritic cell neoplasm
Venetoclax
Targeted therapy
Allogeneic hematopoietic stem cell transplantation
Online Access:http://www.sciencedirect.com/science/article/pii/S2213048923000201

Internet

http://www.sciencedirect.com/science/article/pii/S2213048923000201

Similar Items